


Please amend claims 5/20, 22, and 24 as follows.

- 5. (Amended) A method of affecting a biological process characterized by abnormal cell migration through a physiological barrier, [said] the method comprising administering the composition of claim 1 to a mammal experiencing [said] the biological process in an amount to affect [said] the biological process.
- 6. (Amended) The method of claim 5, wherein [said] <u>the</u> biological process is selected from the group consisting of angiogenesis, organogenesis, ovulation, inflammation, cancer, tumor cell invasion and metastasis, and atherosclerosis.
  - 7. (Amended) The method of claim 5, wherein [said] the mammal is a human.
- 8. (Amended) A method of inhibiting PAI-1-dependent adhesion of a cell to a tissue of a mammal, [said] the method comprising administering to [said] the tissue the composition of claim 1 in an amount to inhibit adhesion of [said] the cell to [said] the tissue.
- 9. (Amended) The method of claim 8, wherein [said] the tissue is in vivo in [said] the mammal.
  - 10. (Amended) The method of claim 8, wherein [said] the mammal is a human.
- 11. (Amended) A method of promoting clearance of scuPA from the surface of a mammalian cell, [said] the method comprising administering the composition of claim 1 to [said] the cell in an amount to promote clearance of [said] the scuPA from [said] the cell.



- 13. (Amended) The method of claim 12, wherein [said] the composition is administered *in vivo* in [said] the human.
- 14. (Amended) A method of impeding pathological migration of a cell in a mammal, [said] the method comprising administering to [said] the mammal the composition of claim 1 in an amount effective to impede pathological migration of [said] the cell.
- 15. (Amended) The method of claim 14, wherein [said] <u>the</u> composition is administered to [said] <u>the</u> mammal at the site of a tumor in [said] <u>the</u> mammal.
  - 16. (Amended) The method of claim 14, wherein [said] the mammal is a human.
- 17. (Amended) A method of inhibiting PAI-1 activity in a tissue of a mammal, [said] the method comprising administering to [said] the tissue the composition of claim 1 in an amount effective to inhibit PAI-1 activity in [said] the tissue.
  - 18. (Amended) The method of claim 17, wherein [said] the mammal is a human.
- 19. (Amended) The method of claim 18, wherein [said] <u>the</u> composition is administered *in vivo* in [said] <u>the</u> human.
- 20. (Amended) A kit comprising a peptide having the amino acid sequence  $X_1X_2X_3X_4X_5X_6X_7X_8$ , wherein:
  - X<sub>1</sub> is hydrogen, an amino-terminal blocking group, or one to twenty amino acid residues;
  - X<sub>2</sub> is an amino acid selected from the group consisting of D, E, H, K, and R;
  - X<sub>3</sub> is an amino acid selected from the group consisting of E and D;